Finally, to better clarify HATs and HDACs implication in the unbalance regulation of brain cells in the biological processes, we performed pharmacological inhibitions through the general HDAC inhibitor, suberanilohydroxamic acid (SAHA; Zhou et al., 2011), approved by FDA for cancer therapy, and the natural compound, curcumin, a specific HAT p-300 activity inhibitor (Sunagawa et al., 2018), in both the AGC1 deficiency models of siAGC1 Oli-neu cells and AGC1± mice-derived neurospheres. Here, HDAC9 is linked to cancer.